Radiopharm Reports Positive Phase 1 Imaging Data for RAD301 in Pancreatic Cancer
RADX is trading near its 52-week low of $2.044 (5.2% above the low) on light trading volume (0.4× avg).
Summary
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 in pancreatic cancer, showing significant tumor uptake and a favorable safety profile, supporting advancement to Phase 2.
Key Events · Product Development and Regulatory · RADX
-
Positive Phase 1 Imaging Data for RAD301
RAD301 demonstrated significant and selective tumor uptake in pancreatic cancer metastases across all evaluable patients, with a favorable safety profile and biodistribution.
-
Low Background Uptake in Key Metastatic Sites
Low background uptake in liver, lung, and bowel supports RAD301's ability to distinguish metastatic lesions from surrounding normal tissue, addressing a limitation of conventional FDG PET imaging.
-
Path to Phase 2 Development
The company stated the results support advancement of RAD301 into a Phase 2 imaging trial, with potential future theranostic applications targeting αvβ6-integrin.
-
Clinical Validation Amid Cash Constraints
The positive data arrives as Radiopharm operates under a going-concern warning with A$4.14M in cash reported on August 28, 2026, making pipeline validation critical for future financing.
Analysis · RADX · Life Sciences
Positive Phase 1 imaging data for RAD301, Radiopharm Theranostics' αvβ6-integrin-targeted radiopharmaceutical for pancreatic ductal adenocarcinoma, was announced today. The trial showed a favorable safety profile, favorable biodistribution, and significant tumor uptake in metastatic lesions across all evaluable patients. Low background uptake in liver, lung, and bowel—common sites of pancreatic cancer spread—supports RAD301's potential to distinguish metastases from normal tissue. This is a meaningful clinical milestone for a company with a going-concern warning and only A$4.14M in cash as of its last report, as it validates a key pipeline asset and supports advancement into Phase 2 development. The data also strengthens the case for a future theranostic pairing, potentially expanding RAD301's commercial opportunity beyond diagnostics.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $2.04 to $16.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.